GSK Using Collaborations to Build China Neuroscience R&D
October 10, 2016 at 05:21 AM EDT
GlaxoSmithKline plans to strengthen its China R&D efforts, using collaborations to develop new neurological treatments. The research update came from GSK's Min Li, PhD, who holds the dual titles of Global Head of Neurosciences and General Manager of R&D China. Established in 2007, GSK's Shanghai R&D Center focuses on neurology. "In the field of neurological diseases, we are very much committed to neurodegeneration and neuroexcitation," said Dr. Li. So far, GSK has established partnerships with scientists at four China universities. More details... Stock Symbol: (NYSE: GSK) Share this with colleagues: // //